Masimo (NASDAQ: MASI) today announced the global launch of
iSirona™, a compact, versatile connectivity hub designed to
maximize interoperability across the continuum of care. The iSirona
hub offers an efficient way to physically connect up to six medical
devices at the bedside and automatically route the data to the
Masimo Hospital Automation™ platform, a vendor-agnostic
connectivity solution for EMR integration, surveillance monitoring,
alarm management, mobile notifications, smart displays, and
analytics. Supplemented by iSirona, Masimo Root®—a powerful,
versatile, multimodal patient monitoring and connectivity solution
combining numerous advanced measurements with sophisticated
expansion capabilities—helps ensure that whatever the source, all
patient data can be accurately and efficiently captured and
presented to clinicians in the most suitable ways.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210119005376/en/
Masimo iSirona™ and the Hospital
Automation™ Platform (Graphic: Business Wire)
iSirona, Root, and the Hospital Automation platform are already
compatible with an ever growing list of more than 500 medical
devices. With its focus on versatility and compatibility, iSirona
is particularly valuable as an easy but robust way for hospitals to
connect almost all medical devices, regardless of brand—helping
reduce the time spent manually charting patient data and instances
of transcription errors, while promoting efficient workflows by
giving clinicians access to patient data wherever, whenever, and
however they want to see it.
With its compact and fan-less design, iSirona is ideal for
connecting multiple patient monitors, anesthesia machines, pumps,
and other medical devices in operating rooms and ICUs where space
is often restricted. The included multi-slotted mounting bracket
allows iSirona to be fixed in a room or mounted directly to a
mobile medical device (such as a ventilator) to provide
connectivity wherever the medical device is used. The onboard
rechargeable battery and local storage allow the iSirona to
continue operating and buffering data for up to two hours in the
event of a power outage or loss of network connectivity, helping
reduce potential loss of data during emergencies and ensuring data
continuity during patient transport. With software-configurable USB
and Bluetooth® connections, iSirona is designed to integrate
today’s physical medical devices and support wireless and wearable
devices in the future, as well as provide utility in both high- and
low-acuity areas throughout the hospital.
In addition to iSirona and Root, the Hospital Automation
platform encompasses a variety of components that together provide
a holistic, end-to-end hospital data automation solution that
aggregates high-fidelity parametric data, waveforms, and alarms
from Masimo and third-party devices. For example, clinicians can
surveil and remotely monitor patients from a central location, as
well as view alarms, using Masimo Patient SafetyNet™. With Masimo
Replica™, real-time monitoring data and alarm notifications can be
relayed to mobile devices, reaching clinicians wherever they
are—even beyond the hospital. Masimo UniView™ brings together data
from multiple devices on an enlarged display that can be tailored
for each patient case, helping ensure that data is visualized for
clinical teams as usefully as possible. And Masimo Iris Analytics™
transforms data into richly detailed, customizable patient and even
hospital-wide reports.
Joe Kiani, Founder and CEO of Masimo, said, “We believe that
Masimo’s Hospital Automation platform is the most customizable,
versatile, and future-focused connectivity solution on the market.
We continue to deepen our understanding of what data clinicians
most want to have at their fingertips and how, in the ideal
hospital of tomorrow, it will be available to them—and to develop
monitoring, display, automation, notification, and reporting
solutions that best address these needs now. iSirona, the latest
member of the Hospital Automation family, makes it easier than ever
to add connectivity wherever it’s needed—bringing offline data
online, smoothing workflows, and ultimately, helping clinicians
improve patient care.”
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. Our mission is to improve patient outcomes and reduce
the cost of care. Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, introduced in 1995, has been shown in
over 100 independent and objective studies to outperform other
pulse oximetry technologies.1 Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates,2 improve CCHD screening in newborns,3 and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs.4-7 Masimo SET® is estimated to be used on
more than 200 million patients in leading hospitals and other
healthcare settings around the world,8 and is the primary pulse
oximetry at 9 of the top 10 hospitals according to the 2020-21 U.S.
News and World Report Best Hospitals Honor Roll.9 Masimo continues
to refine SET® and in 2018, announced that SpO2 accuracy on RD SET®
sensors during conditions of motion has been significantly
improved, providing clinicians with even greater confidence that
the SpO2 values they rely on accurately reflect a patient’s
physiological status. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous
monitoring of blood constituents that previously could only be
measured invasively, including total hemoglobin (SpHb®), oxygen
content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen
Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97®. Masimo hospital
automation and connectivity solutions are centered around the
Masimo Hospital Automation™ platform, and include Iris Gateway®,
Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and
Masimo SafetyNet™. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
References
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo iSirona™, Hospital
Automation™, and Root®. These forward-looking statements are based
on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause
our actual results to differ materially and adversely from those
expressed in our forward-looking statements as a result of various
risk factors, including, but not limited to: risks related to our
assumptions regarding the repeatability of clinical results; risks
related to our belief that Masimo's unique noninvasive measurement
technologies, including Masimo iSirona, Hospital Automation, and
Root, contribute to positive clinical outcomes and patient safety;
risks related to our belief that Masimo noninvasive medical
breakthroughs provide cost-effective solutions and unique
advantages; risks related to COVID-19; as well as other factors
discussed in the "Risk Factors" section of our most recent reports
filed with the Securities and Exchange Commission ("SEC"), which
may be obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether
our expectations will prove correct. All forward-looking statements
included in this press release are expressly qualified in their
entirety by the foregoing cautionary statements. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any
obligation to update, amend or clarify these statements or the
"Risk Factors" contained in our most recent reports filed with the
SEC, whether as a result of new information, future events or
otherwise, except as may be required under the applicable
securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210119005376/en/
Masimo Evan Lamb 949-396-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Apr 2023 to Apr 2024